In the NCT04068896 phase 1/2 dose-finding study with a GFRAL antagonist monoclonal antibody in combination therapy, blocking of GFD-15 signaling is evaluated in subjects with advanced solid tumors and pancreatic cancer. This evidence concerns the gene GFRAL and familial pancreatic carcinoma.